Solanezumab

2 papers

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

0 on aging of 11 trials, 4 with no results posted

Humans1
In silico1

Trials

0 on aging of 11

In trials

Alzheimer's disease
Phase 3Completed10 trials
Cognition disorder
Phase 3Results posted1 trial
Dementia
Phase 2/3Results posted2 trials
Cognitive dysfunction
Phase 1Terminated1 trial

Stopped

NCT01127633TerminatedAlzheimer's disease
Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.
NCT01900665TerminatedAlzheimer's disease
Solanezumab did not meet the study's primary endpoint.
NCT02760602TerminatedAlzheimer's disease
Insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit to participants with prodromal AD as defined by study protocol.
NCT02614131TerminatedCognitive dysfunction
New data suggests that insufficient target engagement would be achieved for efficacy.